Substance / Medication

Pasireotide

Overview

Active Ingredient
pasireotide
RxNorm CUI
1364105
Labeler: Recordati Rare Diseases, Inc.Updated: 2026-02-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

5 trials linked to this intervention

5
Total Trials
1
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment.
Gilis-Januszewska Aleksandra, Bronikowska Małgorzata, Binowski Grzegorz et al. · J Med Econ · 2026
PMID: 41518621Meta-Analysis
Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis.
Costanza Flavia, Basile Christian, Chiloiro Sabrina et al. · J Endocrinol Invest · 2025
PMID: 40622518Meta-AnalysisFull text (PMC)
Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis.
Biagetti Betina, Araujo-Castro Marta, Tebe Cristian et al. · Rev Endocr Metab Disord · 2025
PMID: 39527181Meta-AnalysisFull text (PMC)
Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia.
Vega-Beyhart Arturo, Biagetti Betina, Marazuela Mónica et al. · J Clin Endocrinol Metab · 2025
PMID: 40165498Meta-Analysis
Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis.
Aliyeva Turkan, Muniz Juliana, Soares Gustavo Meira et al. · Pituitary · 2024
PMID: 39349787Meta-Analysis
Second line treatment of acromegaly: Pasireotide or Pegvisomant?
Chiloiro Sabrina, Bianchi Antonio, Giampietro Antonella et al. · Best Pract Res Clin Endocrinol Metab · 2022
PMID: 35931640Meta-Analysis
Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis.
Mondin Alessandro, Manara Renzo, Voltan Giacomo et al. · Front Endocrinol (Lausanne) · 2022
PMID: 35846311Meta-AnalysisFull text (PMC)
Meta-Analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.
Dalton Elissa C, Johns Michael S, Rhodes Lori et al. · Am Surg · 2020
PMID: 32870029Meta-Analysis
Meta-analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.
Dalton Elissa C, Johns Michael S, Rhodes Lori et al. · Am Surg · 2020
PMID: 32684027Meta-Analysis
Efficacy of Pasireotide for Prevention of Postoperative Pancreatic Fistula in Pancreatic Surgery: a Systematic Review and Meta-analysis.
Liu Xinchun, Pausch Thomas, Probst Pascal et al. · J Gastrointest Surg · 2020
PMID: 32207077Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pasireotide (substance)
SNOMED CT
704266003
UMLS CUI
C1872203
RxNorm CUI
1364105
Labeler
Recordati Rare Diseases, Inc.

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
5
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.